🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04905537
Recruiting Observational

Study on Early Genetic Screening and Precise Strategy of Neonatal Critical Illness

NCT04905537 · tracked via the Priya Life Science China tracker
Sponsor
Children's Hospital of Fudan University
Phase
Observational
Started
2021-01-01
Last updated
2025-02-20

Condition(s) studied

Genetic ScreeningHereditary DiseaseNewbornStillbirth

Investigational drug(s) / intervention(s)

No intervention

No intervention: It's only observational study. No interventions.

Study summary

The researchers hope to establish an overall program of early genetic screening for neonatal critical illness in China, and to develop precise intervention strategies to assist clinical diagnosis and treatment of hereditary critical illness.

Eligibility

Sex
ALL
Min age
Max age
100 Days
Healthy volunteers
No
Inclusion Criteria: * Postnatal age less than 100 days; * Perinatal death after 20 weeks of gestation (more than 500 g) * Can be retained biological samples for genetic screening; * Biological parent or guardian's informed consent. Exclusion Criteria: * Reluctance of parents to use genetic sequencing data for subsequent research; * Parents under 18 years of age or incapacitated for decision-making; * subjects older than 100 days; * Perinatal death less than 20 weeks of gestation or weight less than 500 g; * Inherited metabolic diseases with chromosomal abnormalities; * Multiple pregnancies; * Lack of access to biological samples from which DNA can be extracted; * Failure to sign informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Children's Hospital of Fudan University Shanghai Shanghai Municipality Recruiting

More Children's Hospital of Fudan University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04905537 on ClinicalTrials.gov ↗ ← All trials in China